Compass Therapeutics Inc (CMPX) Stock Price, Quote & News

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8099

Website: www.compasstherapeutics.com

Address:

80 Guest Street, Suite 601, Boston, United States

ZephyrsDrift Apr. 25 at 7:48 PM

Trending tickers to look at Next week 4/27: They are all going to be money! 🤑 $MITQ $POET $OSRH $CAST $CMPX

1 · Reply

Groggok Apr. 25 at 6:04 PM

$CMPX INTERESTING data from COMPANION-002 but a hidden wrinkle worth watching 👀 Non-CR/Non-PD patients: 8.1% in combo arm vs 3.5% in paclitaxel alone These pts had no measurable lesions at baseline — they tend to live longer regardless of treatment ORR bias ran against the combo arm… but PFS/OS bias could run in favor of it FDA will want sensitivity analyses.

1 · Reply

WarrenPuffett Apr. 25 at 5:34 PM

$CMPX excited for the readout

0 · Reply

Monkey7779192 Apr. 25 at 4:22 PM

$CMPX My only confidence here is the preannounced Friday after hours to release data on a Monday. Most readouts i seen that do this been positive. If its crap then they won't do a preannouncement and release data on any day. Same with $NTLA. But im more comfident on this as data came early for them. Any thoughts? Quite nervous ofcourse. I bought both hoping both pops. Or one pops hedging the other. Sticking to one seems risky too no hedge. Losing both bets is very unlucky. But winning both is also very lucky. Any thoughts to add?

1 · Reply

outlawinvestor1 Apr. 25 at 3:51 PM

$CMPX worth noting that the tovecimig + pax arm already beats folfox at the 2 month mark AND this is in a much weaker patient population following updated triplet therapy (including a i/o drug) that ABC-006 patients did not experience.

1 · Reply

Br331 Apr. 25 at 2:38 PM

$CMPX best pharma in years

0 · Reply

CFJHauser Apr. 25 at 2:25 PM

$CMPX Looking for HR < 0.50 would be a knockout and we could see 20$ on monday with a range perhaps going to 30$ if we have late entries chasing it following days.

0 · Reply

DeepView101 Apr. 25 at 1:59 PM

$CMPX at this point it’s all about the integrity and quality of Management. They know they need to hit modified OS, and is this pre-announcement a genuine endorsement of hitting that goal or manipulation and a spin story. Don’t know this Management well enough, but thoughts welcomed! GLTA.

1 · Reply

JLCw Apr. 25 at 1:07 PM

Final Watchlist 27/04 $CMPX setting up into Monday webcast. Its a bigger float so slower mover but catalyst is there. Watching 5.80 for continuation $OSRH holding around 0.70 after the move. It's building around here, but needs 0.72 to break before it can push higher $ADTX ultra low float holding after the move. Can move fast but still dealing with supply. Watching over 0.39 for continuation $MITQ steady setup with PR flow + contracts backing it. Building under 0.72, needs that break to open upside $DKI holding around 0.65 after the move. Looks tight but volume not fully there yet. Needs 0.68 to start moving again JL

1 · Reply

Monkey7779192 Apr. 25 at 8:40 AM

$CMPX Whats odds of this not popping on Monday?

1 · Reply

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Mar 5, 2026, 7:30 AM EST - 7 weeks ago

Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

Jan 14, 2026, 10:30 AM EST - 3 months ago

Compass Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 3 months ago

Compass Therapeutics Provides Corporate Update

Jan 5, 2026, 4:30 PM EST - 3 months ago

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2026, 8:00 AM EST - 3 months ago

Compass Therapeutics Announces Key Leadership Appointments

Dec 17, 2025, 7:30 AM EST - 4 months ago

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

Dec 4, 2025, 10:00 AM EST - 5 months ago

Compass Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:00 AM EST - 5 months ago

Compass Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 5 months ago

Compass Therapeutics to Participate in Upcoming December Investor Events

Nov 20, 2025, 7:30 AM EST - 5 months ago

Compass Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:00 PM EST - 5 months ago

Compass Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 3:30 PM EST - 5 months ago

Compass Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 6 months ago

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 9:00 AM EST - 6 months ago

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 3, 2025, 8:00 AM EST - 6 months ago

Compass Therapeutics to Participate in Upcoming November Investor Events

Sep 9, 2025, 5:35 PM EDT - 8 months ago

Compass Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 11:00 AM EDT - 8 months ago

Compass Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 2:10 PM EDT - 8 months ago

Compass Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 26, 2025, 8:00 AM EDT - 8 months ago

Compass Therapeutics to Participate in Upcoming September Investor Events

Aug 12, 2025, 10:28 PM EDT - 9 months ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Compass Therapeutics Announces Proposed Public Offering

Aug 11, 2025, 8:00 AM EDT - 9 months ago

Compass Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 9 months ago

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2025, 4:01 PM EDT - 9 months ago

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Jun 5, 2025, 11:05 AM EDT - 11 months ago

Compass Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:00 AM EDT - 11 months ago

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 20, 2025, 11:30 AM EDT - 1 year ago

Compass Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 8, 2025, 1:30 PM EDT - 1 year ago

Compass Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in Upcoming May Investor Events

$Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting$

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Apr 8, 2025, 3:00 PM EDT - 1 year ago

Compass Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Compass Therapeutics Transcript: Study Update

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Feb 6, 2025, 9:00 AM EST - 1 year ago

Compass Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Dec 10, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Dec 4, 2024, 9:50 AM EST - 1 year ago

Compass Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 9:00 AM EST - 1 year ago

Compass Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Compass Therapeutics to Participate in Upcoming Investor Events

Nov 12, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2024, 10:05 AM EST - 1 year ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 10:31 AM EDT - 1 year ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Sep 9, 2024, 11:00 AM EDT - 1 year ago

Compass Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

May 28, 2024, 4:10 PM EDT - 2 years ago

Compass Therapeutics Announces CEO Transition

May 23, 2024, 5:05 PM EDT - 2 years ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

May 14, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Apr 9, 2024, 12:00 PM EDT - 2 years ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 8:00 AM EST - 2 years ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Nov 9, 2023, 7:30 AM EST - 2 years ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 22, 2023, 4:05 PM EDT - 3 years ago

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

May 4, 2023, 8:30 AM EDT - 3 years ago

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Apr 19, 2023, 8:30 AM EDT - 3 years ago

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Mar 15, 2023, 8:30 AM EDT - 3 years ago

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 2, 2023, 8:30 AM EST - 3 years ago

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Jan 23, 2023, 8:30 AM EST - 3 years ago

Compass Therapeutics Transcript: Study Result

Jan 19, 2023, 5:00 PM EST - 3 years ago

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

Jan 6, 2023, 8:30 AM EST - 3 years ago

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

ZephyrsDrift Apr. 25 at 7:48 PM

Trending tickers to look at Next week 4/27: They are all going to be money! 🤑 $MITQ $POET $OSRH $CAST $CMPX

1 · Reply

Groggok Apr. 25 at 6:04 PM

1 · Reply

WarrenPuffett Apr. 25 at 5:34 PM

$CMPX excited for the readout

0 · Reply

Monkey7779192 Apr. 25 at 4:22 PM

1 · Reply

outlawinvestor1 Apr. 25 at 3:51 PM

1 · Reply

Br331 Apr. 25 at 2:38 PM

$CMPX best pharma in years

0 · Reply

CFJHauser Apr. 25 at 2:25 PM

$CMPX Looking for HR < 0.50 would be a knockout and we could see 20$ on monday with a range perhaps going to 30$ if we have late entries chasing it following days.

0 · Reply

DeepView101 Apr. 25 at 1:59 PM

1 · Reply

JLCw Apr. 25 at 1:07 PM

1 · Reply

Monkey7779192 Apr. 25 at 8:40 AM

$CMPX Whats odds of this not popping on Monday?

1 · Reply

focafoca99 Apr. 25 at 6:00 AM

$CMPX plans to announce topline secondary endpoints from the Phase 2/3 COMPANION-002 study of tovecimig.

0 · Reply

HamBoneXoXo Apr. 25 at 5:51 AM

$CMPX Company prepares a PR which is then released immediately as market closed at 4 to tell everyone we got data to be released Monday pre market 8 am. The stock then goes up .6 cents after hrs. Study been going on for three yrs abd three month. Surely a binary on Monday best to be sitting it out by me. The best risk strategy for these bios is not to take it. Good luck

0 · Reply

WallStreetBuyDip Apr. 25 at 3:09 AM

my take on $CMPX is simple, buy when H% gets low like shown here

0 · Reply

Marcelline Apr. 25 at 2:51 AM

$CMPS why is $CMPX trending? Did people get it confused?

1 · Reply

topstockalerts Apr. 25 at 1:46 AM

After Hours Top Gainers PT2 $SMX $PLBL $CMPX $TORO $NEXR

0 · Reply

Monkey7779192 Apr. 25 at 12:41 AM

$CMPX I will dig in more over the weekend and decide.

0 · Reply

AlertsAndNews Apr. 24 at 11:29 PM

Gappers in after hours trading $DKI $ADTX $NTLA $MITQ $CMPX Thats a wrap for the week! ill update over the weekend.

0 · Reply

Monkey7779192 Apr. 24 at 10:05 PM

$CMPX Why did they say the data should come in April? Quite late into April hence im kinda worried but they doing a preannouncement so kinda a positive sign.

1 · Reply

topstockalerts Apr. 24 at 9:58 PM

After Hours Top Gainers $DKI $NTLA $CMPX $SMX $LSH

0 · Reply

cubie Apr. 24 at 9:36 PM

$CMPX did cubie got this trending , my bad😅. it was @judgeyoung2 who let cubie know data on monday

1 · Reply

Jumpmanz Apr. 24 at 9:35 PM

$CMPX

0 · Reply

4Reel Apr. 24 at 9:29 PM

$CMPX they originally expected to reach the 80% number in 3Q for secondary endpoints, PFS and OS, they didnt reach it until 1Q of 2026. There is no fda approved second line for BTC eitger.

1 · Reply

Market Cap	938.26M
Revenue (ttm)	0.00
Net Income (ttm)	-66.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,058,800
Avg Vol	2,420,458
Day's Range	N/A - N/A
Shares Out	180.09M
Stochastic %K	7%
Beta	1.49
Analysts	Strong Sell
Price Target	$13.62